Men's Health: Natural approaches for better prostate health Men's Health | Page 48

Men ’ s Health : Natural health approaches for better prostate health
Astragalus radix extracts and Soybean extracts were combined into one 500 mg UMOOZE ® tablet and it is considered a food supplement . The objective of this study was to evaluate the benefits of UMOOZE ® as an add-on therapy for BPH by evaluating the improvements in symptoms of BPH , which were assessed according to the International Prostate Symptom Score ( IPSS ) and Quality of Life ( QoL ) index . The IPSS is a validated 7-item urinary symptoms severity scale .
Each subject received UMOOZE ® or a placebo . In this add-on study , the product was administered twice daily for 56 days . The benefits were evaluated at the baseline and subsequently on Day 28 , Day 42 and Day 56 , including the IPSS Index , QoL index , Qmax , PVR , prostate volume and Prostate-Specific antigen ( PSA ) test .
The study included the following inclusion criteria :
• Male – 40 years of age or older
• Screened by inquiry and diagnosed with BPH based on the result of a digital rectal examination ( DRE ) or transrectal ultrasonography ( TRUS )
• Prostate volume ≥ 20 cm3
• Has complained of voiding symptoms related to BPH
• Has an IPSS ≥ 13 or a UFR measure of Qmax <= 15 ml / sec together with a voided volume ≥ 150 ml
• Serum PSA < 6.5 ng / ml
• Has been treated with medication for BPH
• Informed consent form signed
Men that were excluded from the study had the following criteria :
• Sensitivity to study product
• Had received prostatic surgery for BPH during the past 24 weeks
• Hard nodule found by DRE
• Ongoing neurogenic bladder , urinary tract infection , bladder stone , urethral stricture , bladder cancer , prostate cancer , severe liver dysfunction , severe renal dysfunction or severe cardiovascular disease
• Patient has clinically significant physical disability or abnormal findings in physical examination or laboratory testing judged by the investigator or co-investigator
• Participation in any clinical investigation during the last 30 days
• Individuals are judged by the investigators or co-investigator to be undesirable as subjects
43